"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
Descriptor ID |
D003362
|
MeSH Number(s) |
N03.219.151.125
|
Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 0 | 1 | 1 |
1994 | 1 | 3 | 4 |
1995 | 0 | 3 | 3 |
1996 | 1 | 4 | 5 |
1997 | 3 | 4 | 7 |
1998 | 1 | 8 | 9 |
1999 | 1 | 8 | 9 |
2000 | 0 | 9 | 9 |
2001 | 2 | 8 | 10 |
2002 | 0 | 7 | 7 |
2003 | 0 | 7 | 7 |
2004 | 1 | 3 | 4 |
2005 | 1 | 7 | 8 |
2006 | 0 | 5 | 5 |
2007 | 2 | 11 | 13 |
2008 | 2 | 11 | 13 |
2009 | 1 | 9 | 10 |
2010 | 0 | 11 | 11 |
2011 | 0 | 12 | 12 |
2012 | 0 | 10 | 10 |
2013 | 1 | 9 | 10 |
2014 | 2 | 11 | 13 |
2015 | 3 | 13 | 16 |
2016 | 4 | 17 | 21 |
2017 | 6 | 8 | 14 |
2018 | 3 | 15 | 18 |
2019 | 6 | 15 | 21 |
2020 | 6 | 17 | 23 |
2021 | 5 | 15 | 20 |
2022 | 0 | 13 | 13 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors. J Clin Oncol. 2023 Feb 10; 41(5):1046-1058.
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
-
Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer. Nat Commun. 2022 09 29; 13(1):5566.
-
Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated With Uveitis in the United States: A Cost-Effectiveness Analysis. Value Health. 2022 10; 25(10):1705-1716.
-
The Economic Evaluation of Team Clinic-Group Approach to a Care Model of Early Adolescents With Type 1 Diabetes. J Pediatr Health Care. 2022 Sep-Oct; 36(5):430-437.
-
Universal first-trimester cytomegalovirus screening and valaciclovir prophylaxis in pregnant persons: a cost-effectiveness analysis. Am J Obstet Gynecol MFM. 2022 09; 4(5):100676.
-
A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value Health. 2022 08; 25(8):1298-1306.
-
Post-fracture care programs for prevention of subsequent fragility fractures: a literature assessment of current trends. Osteoporos Int. 2022 Aug; 33(8):1659-1676.
-
The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value Health. 2022 08; 25(8):1336-1343.
-
Cost-Effectiveness of Recommendations From the Surgeon General's Call-to-Action to Control Hypertension. Am J Hypertens. 2022 03 08; 35(3):225-231.